Media Release

January 23, 2003 01:15 ET | Source: Novartis Pharma AG Novartis Pharma AG

For release content, please refer to the attachment.

Attachments

Media Release...

Recommended Reading

March 23, 2026 02:15 ET | Source: Novartis Pharma AG

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence...
Read More
March 20, 2026 02:00 ET | Source: Novartis Pharma AG

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,...
Read More